Co-Authors
This is a "connection" page, showing publications co-authored by Mark Denison and Maria Agostini.
Connection Strength
2.164
-
Small-Molecule Antiviral ß-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. J Virol. 2019 12 15; 93(24).
Score: 0.854
-
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018 03 06; 9(2).
Score: 0.758
-
The coronavirus proofreading exoribonuclease mediates extensive viral recombination. PLoS Pathog. 2021 01; 17(1):e1009226.
Score: 0.231
-
Fitness Barriers Limit Reversion of a Proofreading-Deficient Coronavirus. J Virol. 2019 10 15; 93(20).
Score: 0.211
-
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020 07 21; 32(3):107940.
Score: 0.056
-
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 04 29; 12(541).
Score: 0.055